Hooshmand Sheshbaradaran
Chief Operating Officer chez BETTERLIFE PHARMA INC.
Fortune : 97 040 $ au 31/03/2024
Profil
Hooshmand Sheshbaradaran is the founder of Niiki Pharma, Inc. He currently holds the position of Director at Bold Therapeutics, Inc. since 2019 and is also the Chief Operating Officer at BetterLife Pharma, Inc. His former positions include Director-Oncology & New Products Marketing at Pfizer Inc., Director-Oncology Business Development at F.
Hoffmann-La Roche Ltd., Director-Oncology & New Products Marketing at Pharmacia Corp., Director & Chief Development Officer at Intezyne Technologies, Inc. from 2013 to 2019, Principal at Zeneus Pharma Ltd., and Chief Business Officer at Akamis Bio Ltd.
He obtained a doctorate degree from Karolinska Institutet.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BETTERLIFE PHARMA INC.
1,22% | 08/12/2023 | 1 386 281 ( 1,22% ) | 97 040 $ | 31/03/2024 |
Postes actifs de Hooshmand Sheshbaradaran
| Sociétés | Poste | Début |
|---|---|---|
| BETTERLIFE PHARMA INC. | Chief Operating Officer | - |
Niiki Pharma, Inc.
 Niiki Pharma, Inc. Pharmaceuticals: OtherHealth Technology Niiki Pharma, Inc. manufactures chemicals and botanical products. It specializes in cancer treatments directed at novel cellular targets and related companion diagnostics. The company was founded by Hooshmand Sheshbaradaran, Ardakana Ali and Jay Z. Zhang in 2007 and is headquartered in Hoboken, NJ. | Founder | - |
Bold Therapeutics, Inc.
 Bold Therapeutics, Inc. BiotechnologyHealth Technology Bold Therapeutics, Inc. is a Canadian clinical-stage biopharmaceutical company that was founded in 2018 by a team of industry veterans to develop and commercialize novel therapeutics. The company is based in Vancouver, Canada. The company's focus is on developing Bold-100, a drug that has the potential to significantly improve outcomes in a wide range of both solid and liquid tumors in combination with other anticancer therapies. Edward Russell McAllister has been the CEO of the company since 2018. | Director/Board Member | 01/01/2019 |
Anciens postes connus de Hooshmand Sheshbaradaran
| Sociétés | Poste | Fin |
|---|---|---|
Intezyne Technologies, Inc.
 Intezyne Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Intezyne Technologies, Inc. develops therapeutic and diagnostic technologies. The firm is a clinical stage biotechnology company. The company was founded by Habib Skaff and Kevin N. Sill in 2004 and is headquartered in Tampa, FL. | Director/Board Member | 02/01/2019 |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Corporate Officer/Principal | - |
| PFIZER, INC. | Sales & Marketing | - |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Sales & Marketing | - |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
Formation de Hooshmand Sheshbaradaran
| Karolinska Institutet | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| BETTERLIFE PHARMA INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Zeneus Pharma Ltd.
 Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | Distribution Services |
Niiki Pharma, Inc.
Niiki Pharma, Inc. Pharmaceuticals: OtherHealth Technology Niiki Pharma, Inc. manufactures chemicals and botanical products. It specializes in cancer treatments directed at novel cellular targets and related companion diagnostics. The company was founded by Hooshmand Sheshbaradaran, Ardakana Ali and Jay Z. Zhang in 2007 and is headquartered in Hoboken, NJ. | Health Technology |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Intezyne Technologies, Inc.
Intezyne Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Intezyne Technologies, Inc. develops therapeutic and diagnostic technologies. The firm is a clinical stage biotechnology company. The company was founded by Habib Skaff and Kevin N. Sill in 2004 and is headquartered in Tampa, FL. | Commercial Services |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Bold Therapeutics, Inc.
Bold Therapeutics, Inc. BiotechnologyHealth Technology Bold Therapeutics, Inc. is a Canadian clinical-stage biopharmaceutical company that was founded in 2018 by a team of industry veterans to develop and commercialize novel therapeutics. The company is based in Vancouver, Canada. The company's focus is on developing Bold-100, a drug that has the potential to significantly improve outcomes in a wide range of both solid and liquid tumors in combination with other anticancer therapies. Edward Russell McAllister has been the CEO of the company since 2018. | Health Technology |
